IMPACT Score for Traumatic Brain Injury Outcome
International Mission for Prognosis and Clinical Trial design in TBI (IMPACT). Predicts 6-month outcome (death or vegetative state) in patients with moderate-severe TBI. Core, CT, and Lab models available.
Score interpretation
IMPACT (core + CT + lab) predicted 6-month mortality below 20 %.
→ Use alongside clinical assessment; not for individual treatment limitation.
IMPACT predicted 6-month mortality 20–50 %.
→ Discuss prognosis with neurosurgery / neurocritical care.
IMPACT predicted 6-month mortality 50 % or more.
→ Senior multidisciplinary discussion; prognostic models inform, not decide, care.
Interpretation bands for the IMPACT Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Methotrexate · Chemotherapy / Immunosuppressant — Head and Neck / Granulomatosis
- Pembrolizumab (Head and Neck SCC) · PD-1 Inhibitor
- Nivolumab (Head and Neck SCC) · PD-1 Inhibitor
- Riluzole · Neuroprotective Agent — ALS/Motor Neurone Disease
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.